By Counterforce Health Team in Mepsevii (vestronidase alfa-vjbk) —

Do You Qualify for Mepsevii Coverage by Aetna (CVS Health) in Michigan? Decision Tree & Appeal Guide

Answer Box: Getting Mepsevii Covered in Michigan

To get Mepsevii (vestronidase alfa-vjbk) covered by Aetna (CVS Health) in Michigan, you need: (1) confirmed MPS VII diagnosis via enzyme assay or genetic testing, (2) elevated urinary glycosaminoglycans (uGAG) at least 2x normal, and (3) specialist prescriber documentation. Submit the Aetna Mepsevii precertification form with complete clinical records. If denied, you have 127 days to file an external review with Michigan DIFS. Start by gathering diagnostic test results and scheduling with a metabolic specialist today.

Table of Contents

  1. How to Use This Guide
  2. Eligibility Triage: Do You Qualify?
  3. If "Likely Eligible": Your Approval Checklist
  4. If "Possibly Eligible": Tests You Need
  5. If "Not Yet": Alternative Paths
  6. If Denied: Michigan Appeal Options
  7. Coverage Requirements at a Glance
  8. Common Denial Reasons & Fixes
  9. FAQ: Your Top Questions Answered
  10. Sources & Further Reading

How to Use This Guide

This decision tree helps you determine whether you qualify for Mepsevii (vestronidase alfa-vjbk) coverage through Aetna (CVS Health) in Michigan. Work through each section in order—the eligibility triage will point you to the right next steps based on your current situation.

Important: Mepsevii is the only FDA-approved enzyme replacement therapy for MPS VII (Sly syndrome), making it medically necessary for confirmed cases. However, Aetna requires specific documentation to prove medical necessity and rule out alternative treatments.

Note: This guide covers commercial Aetna plans. Medicare Advantage and Medicaid managed care plans may have different requirements.

Eligibility Triage: Do You Qualify?

Answer these questions to determine your likelihood of approval:

✅ Likely Eligible if you have ALL of these:

  • Confirmed MPS VII diagnosis via enzyme assay showing deficient beta-glucuronidase activity OR genetic testing confirming MPS VII
  • Elevated urinary glycosaminoglycans (uGAG) at least 2 times the mean normal for age
  • Prescription from or consultation with a metabolic disease specialist
  • Complete medical records documenting MPS VII symptoms and progression

⚠️ Possibly Eligible if you have SOME of these:

  • Clinical suspicion of MPS VII but incomplete diagnostic testing
  • Family history of MPS VII with some symptoms
  • Elevated uGAG but no enzyme testing yet
  • Primary care provider willing to refer to specialist

❌ Not Yet if you have:

  • No confirmed MPS VII diagnosis
  • Normal enzyme levels and uGAG
  • Severe, irreversible cognitive impairment (may require exception request)
  • No specialist involvement

If "Likely Eligible": Your Approval Checklist

Step 1: Gather Required Documentation

Before submitting your prior authorization, collect these items:

Medical Records:

  • MPS VII diagnosis confirmation (enzyme assay or genetic test results)
  • Urinary glycosaminoglycan (uGAG) levels showing elevation ≥2x normal
  • Specialist consultation notes from metabolic disease specialist
  • Baseline functional assessments (6-minute walk test, motor function, organ volumes)
  • Complete medical history documenting MPS VII symptoms

Insurance Information:

  • Current Aetna member ID and policy details
  • Prescription benefit verification
  • Any prior authorization history for other medications

Step 2: Complete the Aetna Mepsevii Form

Download and complete the Aetna Mepsevii precertification form. Your specialist must:

  • Confirm MPS VII diagnosis with supporting lab values
  • Document elevated uGAG levels with specific measurements
  • Provide clinical rationale for enzyme replacement therapy
  • Include baseline functional status measurements

Step 3: Submit Your Request

Electronic submission (recommended):

  • Availity provider portal
  • CoverMyMeds platform
  • Electronic Medical Record (EMR) integration

Alternative methods:

  • Fax: Use number provided on precertification form
  • Phone: 1-888-632-3862 (commercial plans)

Timeline: Submit at least 2 weeks before planned treatment start. Aetna typically responds within 30-45 days for standard requests, 72 hours for expedited.

If "Possibly Eligible": Tests You Need

Missing Diagnostic Confirmation

Next steps:

  1. Request referral to metabolic specialist or geneticist
  2. Schedule enzyme assay for beta-glucuronidase activity
  3. Order genetic testing for GUSB gene mutations
  4. Collect 24-hour urine for glycosaminoglycan measurement

Timeline: Allow 4-6 weeks for test results and specialist consultation before submitting PA request.

Incomplete Clinical Documentation

What to track:

  • Document all MPS VII symptoms with photos/videos when appropriate
  • Track functional decline or stability with standardized assessments
  • Maintain detailed symptom diary
  • Schedule baseline imaging (skeletal surveys, organ measurements)

If "Not Yet": Alternative Paths

Exception Request Strategy

If you don't meet standard criteria, you can request a formulary exception:

Required documentation:

  • Detailed letter of medical necessity from specialist
  • Literature supporting off-label use (if applicable)
  • Documentation of why no alternatives exist for MPS VII
  • Evidence that delay would cause irreversible harm

Supportive Care Documentation

While pursuing Mepsevii approval:

  • Document current supportive treatments and their limitations
  • Track disease progression with objective measurements
  • Maintain specialist follow-up for ongoing evaluation
  • Consider participation in patient registries or clinical studies

If Denied: Michigan Appeal Options

Michigan provides robust appeal rights under the Patient's Right to Independent Review Act. Here's your pathway:

Level 1: Internal Appeal with Aetna

Timeline: File within 60 days of denial notice Process: Submit appeal with additional clinical documentation Decision time: 30 days (standard), 72 hours (expedited)

Level 2: Peer-to-Peer Review

Request a clinical discussion between your specialist and Aetna's medical director. This often resolves denials when medical necessity is clearly documented.

Level 3: Michigan DIFS External Review

Who can file: Patient or authorized representative Timeline: 127 days from Aetna's final denial Forms: Michigan DIFS External Review Request Decision time: 60 days (standard), 72 hours (expedited with physician certification) Cost: No fee for patients Decision: Binding on Aetna

From our advocates: "We've seen MPS VII cases succeed at external review when the initial denial focused on cost rather than medical necessity. The key was submitting peer-reviewed literature showing Mepsevii's unique role as the only FDA-approved ERT for this condition, along with clear documentation of the patient's functional decline without treatment."

Contact DIFS:

Coverage Requirements at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before coverage Aetna provider portal Aetna PA List
MPS VII Diagnosis Confirmed via enzyme/genetic testing Specialist consultation Aetna Policy
Elevated uGAG ≥2x normal for age Lab results Aetna Policy
Specialist Prescriber Metabolic disease specialist required Provider credentials Aetna Policy
Dosing 4 mg/kg IV every 2 weeks FDA prescribing information FDA Label
Site of Care Infusion center or hospital Administration requirements FDA Label

Common Denial Reasons & Fixes

Denial Reason How to Overturn Required Documentation
"Not medically necessary" Submit specialist letter with FDA indication FDA label, peer-reviewed studies, specialist attestation
"Experimental/investigational" Emphasize FDA approval for MPS VII FDA approval letter, prescribing information
"Insufficient documentation" Provide complete diagnostic workup Enzyme assay, genetic testing, uGAG levels
"Step therapy required" Document no alternatives exist Literature showing Mepsevii is only ERT for MPS VII
"Quantity limits exceeded" Justify weight-based dosing FDA dosing guidelines, patient weight documentation

FAQ: Your Top Questions Answered

Q: How long does Aetna prior authorization take in Michigan? A: Standard requests: 30-45 days. Expedited (urgent medical need): 72 hours. Submit at least 2 weeks before planned treatment start.

Q: What if Mepsevii is non-formulary on my plan? A: Request a formulary exception with medical necessity documentation. Emphasize that Mepsevii is the only FDA-approved treatment for MPS VII.

Q: Can I request an expedited appeal in Michigan? A: Yes. If delay would seriously jeopardize your health, request expedited review with physician certification. DIFS decides within 72 hours.

Q: Does step therapy apply if I haven't tried other treatments? A: No alternatives exist for MPS VII. Document this in your appeal—Mepsevii is the only FDA-approved enzyme replacement therapy for this condition.

Q: How much does Mepsevii cost without insurance? A: Approximately $2,941 per 10-mg vial. Annual costs vary by patient weight, typically $150,000-$300,000+ per year.

Q: Are there patient assistance programs? A: Yes. Contact Ultragenyx patient services at 1-844-887-4877 for copay assistance and foundation grant information.

Q: What happens if DIFS external review denies my appeal? A: You have 60 days to seek judicial review in Michigan circuit court, though this is rare and expensive.

Q: Can my doctor submit the appeal for me? A: Yes, with your written consent. Many specialists are experienced with MPS VII appeals and can provide stronger clinical documentation.

Navigating insurance coverage for rare disease treatments like Mepsevii can feel overwhelming, but Michigan patients have strong appeal rights and multiple pathways to coverage. The key is thorough documentation of your MPS VII diagnosis and the medical necessity for enzyme replacement therapy.

Counterforce Health specializes in turning insurance denials into successful appeals by crafting evidence-backed, payer-specific responses. Their platform analyzes denial letters and plan policies to identify the exact criteria needed for approval, then drafts targeted rebuttals using peer-reviewed literature and clinical guidelines. For complex cases like MPS VII enzyme replacement therapy, having expert appeal support can make the difference between continued denials and life-changing treatment access.

Remember: Mepsevii is FDA-approved and medically necessary for MPS VII patients. Don't let initial denials discourage you from pursuing the treatment you need. Use Michigan's robust appeal process, gather comprehensive documentation, and consider professional appeal assistance if needed.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance plan directly for personalized guidance. For assistance with insurance appeals in Michigan, contact DIFS at 877-999-6442 or visit michigan.gov/difs.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.